SS-31 in mitochondrial disease research: a map of the major trials

Quick answer

For “SS-31: SS-31 in mitochondrial disease research a map,” a prespecified subgroup analysis of the MMPOWER-3 trial found that participants with disease-causing nuclear DNA (nDNA) pathogenic variants who received elamipretide experienced an improvement in the six-minute walk test, while those with mitochondrial DNA (mtDNA) variants did not.¹

This is a subgroup finding from a trial that did not meet its primary endpoints, and the result requires confirmation in a new prospective trial.¹ For Filipino readers, “SS-31: SS-31 in mitochondrial disease research a map” is best read by matching every conclusion to the exact study, population, outcome, and product identity.

What is SS-31, in plain language?

For “SS-31: SS-31 in mitochondrial disease research a map,” start with the recorded result, not the marketing version. A prespecified subgroup analysis of the MMPOWER-3 trial found that participants with disease-causing nuclear DNA (nDNA) pathogenic variants who received elamipretide experienced an improvement in the six-minute walk test, while those with mitochondrial DNA (mtDNA) variants did not.¹

Within “SS-31: SS-31 in mitochondrial disease research a map,” Post hoc analysis of the MMPOWER-3 phase 3 trial.¹ This is a subgroup finding from a trial that did not meet its primary endpoints, and the result requires confirmation in a new prospective trial.¹

For “SS-31: SS-31 in mitochondrial disease research a map,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: SS-31 in mitochondrial disease research a map,” the clearest route is to separate the result from its interpretation. WHO states that some falsified medical products can closely resemble genuine products and may require quality-control analysis.²

Within “SS-31: SS-31 in mitochondrial disease research a map,” WHO guidance on suspected falsified medical products and regulatory laboratory testing.² Appearance alone cannot authenticate a product or establish a research outcome.²

In “SS-31: SS-31 in mitochondrial disease research a map,” the careful reading is narrower than a social-media headline. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

The plain-language rule for “SS-31: SS-31 in mitochondrial disease research a map” is simple: identify what was measured before asking what it might mean elsewhere. A precise answer can still be interesting; it simply keeps the reader oriented.

Readers researching SS-31 can view its live catalog details below. The listing identifies the catalog item and is separate from the evidence discussed here.

What did the first evidence source report?

For “SS-31: SS-31 in mitochondrial disease research a map,” one precise finding is more useful than a broad slogan. SS-31 is a synthetic tetrapeptide that targets the inner mitochondrial membrane, where it binds to cardiolipin to help preserve mitochondrial function and reduce oxidative stress.³

Within “SS-31: SS-31 in mitochondrial disease research a map,” Mechanism of action described in FDA labeling and laboratory research.³ The conclusion should stay within the measured setting.³

That distinction gives “SS-31: SS-31 in mitochondrial disease research a map” a useful answer without making it sound larger than the evidence. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

For “SS-31: SS-31 in mitochondrial disease research a map,” the study becomes easier to read when its boundaries remain visible. The evidence is most useful when every conclusion stays attached to its exact source, study context, and product identity.⁴

Within “SS-31: SS-31 in mitochondrial disease research a map,” Editorial synthesis of the canonical research records and Philippine verification sources.⁴ This synthesis is educational and is not personal medical advice or a product recommendation.⁴

Keeping that boundary visible makes “SS-31: SS-31 in mitochondrial disease research a map” clearer for a general reader. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

A useful magazine explanation of “SS-31: SS-31 in mitochondrial disease research a map” should make the main point easy to find. It should also keep the study boundary close enough that readers do not need to hunt for it.

What did the next result add?

For “SS-31: SS-31 in mitochondrial disease research a map,” a useful summary begins with the outcome the researchers actually recorded. A phase 3 trial (MMPOWER-3) in 218 adults with primary mitochondrial myopathy (PMM) did not meet its primary endpoints of improving the six-minute walk distance or total fatigue score compared to placebo after 24 weeks.⁵

Within “SS-31: SS-31 in mitochondrial disease research a map,” Primary outcome of the randomized, double-blind, placebo-controlled MMPOWER-3 trial.⁵ The conclusion should stay within the measured setting.⁵

This is the point where “SS-31: SS-31 in mitochondrial disease research a map” changes from a claim into an evidence question. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

This reading of “SS-31: SS-31 in mitochondrial disease research a map” avoids two common errors. It does not dismiss a narrow finding, and it does not stretch that finding beyond the question researchers asked.

Which limits belong beside the headline?

For “SS-31: SS-31 in mitochondrial disease research a map,” start with the recorded result, not the marketing version. The compound SS-31 is also known by its research name, elamipretide.⁶

Within “SS-31: SS-31 in mitochondrial disease research a map,” The FDA record for FORZINITY lists the active ingredient as elamipretide hydrochloride, and laboratory studies refer to SS-31 as elamipretide.⁶ The conclusion should stay within the measured setting.⁶

For “SS-31: SS-31 in mitochondrial disease research a map,” that boundary keeps one result from becoming a universal promise. The result can be informative without becoming a personal recommendation or a promise about a catalog item.

How does product identity fit the story?

For “SS-31: SS-31 in mitochondrial disease research a map,” one precise finding is more useful than a broad slogan. In a 12-week randomized trial of 12 males with Barth syndrome, the primary endpoints were the distance walked in six minutes and a patient-reported symptom assessment.⁷

Within “SS-31: SS-31 in mitochondrial disease research a map,” The SPIBA-201 (Part 1) trial described in the FDA Snapshot and the psychometric evaluation of the BTHS-SA.⁷ The FDA Snapshot notes that efficacy was based on the open-label portion of the study, not the randomized comparison.⁷

A catalog card does not change the evidence boundary in “SS-31: SS-31 in mitochondrial disease research a map”.⁴ It helps readers locate a live item while the article keeps scientific and product questions separate.⁴

Readers comparing this topic with MOTS-C can view its live catalog details below. It is a separate catalog reference, not a suggested combination.

What is the practical Philippine reading?

For “SS-31: SS-31 in mitochondrial disease research a map,” a useful summary begins with the outcome the researchers actually recorded. The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸

Within “SS-31: SS-31 in mitochondrial disease research a map,” Official Philippine regulatory verification service.⁸ A portal record applies to the exact product or establishment named in that record.⁸

Bottom line

For “SS-31: SS-31 in mitochondrial disease research a map,” post hoc analysis of the MMPOWER-3 phase 3 trial.¹ This is a subgroup finding from a trial that did not meet its primary endpoints, and the result requires confirmation in a new prospective trial.¹

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸ For “SS-31: SS-31 in mitochondrial disease research a map,” this check belongs beside the science rather than underneath it.

The practical conclusion for “SS-31: SS-31 in mitochondrial disease research a map” is informed interest with exact source, context, and product boundaries intact. That makes the article useful without turning it into a sales promise or a personal recommendation.

Frequently asked questions

What is the fastest way to understand SS-31?

A prespecified subgroup analysis of the MMPOWER-3 trial found that participants with disease-causing nuclear DNA (nDNA) pathogenic variants who received elamipretide experienced an improvement in the six-minute walk test, while those with mitochondrial DNA (mtDNA) variants did not.¹ For “SS-31: SS-31 in mitochondrial disease research a map,” begin there, then keep the study setting and stated limit beside the result instead of jumping to a broader conclusion.

Does one positive finding settle the whole topic?

No. .³ In “SS-31: SS-31 in mitochondrial disease research a map,” a finding can be useful while remaining narrow, early, or tied to one measured outcome.

Why does the study context matter?

Primary outcome of the randomized, double-blind, placebo-controlled MMPOWER-3 trial.⁵ For “SS-31: SS-31 in mitochondrial disease research a map,” changing the population, design, formulation, or outcome changes the question being answered.

What should Filipino readers verify?

The Philippine FDA Verification Portal separates licensed establishments from registered or notified health products.⁸ While reading “SS-31: SS-31 in mitochondrial disease research a map,” check the exact product and establishment details rather than relying on a familiar molecule name.

Do the SS-31 and MOTS-C cards prove a benefit?

No. In “SS-31: SS-31 in mitochondrial disease research a map,” they are live catalog references for navigation. They do not turn a study result into a product claim, prove equivalence, or suggest using the items together.⁴

Sources

Footnotes

1. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.. Post hoc analysis of the MMPOWER-3 phase 3 trial. This is a subgroup finding from a trial that did not meet its primary endpoints, and the result requires confirmation in a new prospective trial. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

2. WHO laboratory analysis of suspected falsified medical products; WHO laboratory testing for health-product regulation. WHO guidance on suspected falsified medical products and regulatory laboratory testing. Appearance alone cannot authenticate a product or establish a research outcome. ↩ ↩² ↩³

3. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.. Mechanism of action described in FDA labeling and laboratory research. ↩ ↩² ↩³ ↩⁴

4. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.; FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function.; Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.; Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Editorial synthesis of the canonical research records and Philippine verification sources. This synthesis is educational and is not personal medical advice or a product recommendation. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

5. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.. Primary outcome of the randomized, double-blind, placebo-controlled MMPOWER-3 trial. ↩ ↩² ↩³ ↩⁴

6. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Mitochondrial-targeted SS-31 peptide attenuates radiation-induced cardiomyocyte senescence.. The FDA record for FORZINITY lists the active ingredient as elamipretide hydrochloride, and laboratory studies refer to SS-31 as elamipretide. ↩ ↩² ↩³

7. FDA Drugs@FDA record for FORZINITY (ELAMIPRETIDE HYDROCHLORIDE); Initial Psychometric Evaluation of the Barth Syndrome Symptom Assessment (BTHS-SA) for Adolescents and Adults in a Phase 2 Clinical Study.. The SPIBA-201 (Part 1) trial described in the FDA Snapshot and the psychometric evaluation of the BTHS-SA. The FDA Snapshot notes that efficacy was based on the open-label portion of the study, not the randomized comparison. ↩ ↩² ↩³

8. Philippine FDA Verification Portal; FDA Advisory No. 2023-2238: Utilization of the FDA Verification Portal. Official Philippine regulatory verification service. A portal record applies to the exact product or establishment named in that record. ↩ ↩² ↩³ ↩⁴ ↩⁵